Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing

Aardvark Therapeutics, Inc. ( (AARD) ) just unveiled an update.

On December 10, 2025, Aardvark Therapeutics announced the dosing of the first patient in Australia for their Phase 3 HERO trial, which evaluates ARD-101 for treating hyperphagia in Prader-Willi syndrome patients. The company has received regulatory clearance for trial sites in Canada and the UK, and with strong enrollment in the US, they anticipate meeting their timeline for topline data by Q3 2026 without activating additional EU sites.

The most recent analyst rating on (AARD) stock is a Buy with a $47.00 price target. To see the full list of analyst forecasts on Aardvark Therapeutics, Inc. stock, see the AARD Stock Forecast page.

Spark’s Take on AARD Stock

According to Spark, TipRanks’ AI Analyst, AARD is a Underperform.

Aardvark Therapeutics, Inc. faces severe financial challenges typical of early-stage pharmaceutical companies, with zero revenue and substantial operational losses. The lack of technical and valuation indicators further contributes to the high-risk profile.

To see Spark’s full report on AARD stock, click here.

More about Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Their lead compound, ARD-101, is in Phase 3 clinical development for hyperphagia associated with Prader-Willi Syndrome, and they are also developing ARD-201, a combination therapy targeting obesity-related conditions.

Average Trading Volume: 191,960

Technical Sentiment Signal: Strong Buy

Current Market Cap: $300.9M

Find detailed analytics on AARD stock on TipRanks’ Stock Analysis page.